Hospital
West Penn Allegheny Health System INC
West Penn Allegheny Health System INC was paid $12.69M by Medicaid between Jun 2019 and Dec 2024, across 274 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 18% of everything it billed.
33Billing provider infoWEST PENN ALLEGHENY HEALTH SYSTEM INC
PITTSBURGH, PA 15224
PITTSBURGH, PA 15224
33aNPI1194744805assigned 07/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.69M
24GClaims355,433
24DCodes billed274
24AFirst – last monthJun 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#26 of 154
Median peer was paid$2.82M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 989 | $15K | |
| 2020 | 47,083 | $2.29M | |
| 2021 | 158,157 | $6.50M | |
| 2022 | 52,932 | $1.44M | |
| 2023 | 60,147 | $1.47M | |
| 2024incomplete | 36,125 | $988K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 18% | 1,127 | 876 | $2.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 9,232 | 8,900 | $1.52M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 8,949 | 8,668 | $1.40M |
| G0378 | Hospital observation service, per hour | 8.8% | 1,936 | 1,695 | $1.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.6% | 7,741 | 7,509 | $1.09M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 7.6% | 14,246 | 12,681 | $960K |
| J9035 | Injection, bevacizumab, 10 mg | 4.8% | 325 | 110 | $603K |
| J9299 | Injection, nivolumab, 1 mg | 3.4% | 313 | 171 | $430K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.8% | 3,466 | 2,080 | $354K |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.8% | 109 | 76 | $234K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 1.8% | 83 | 62 | $224K |
| J0897 | Injection, denosumab, 1 mg | 1.2% | 420 | 385 | $153K |
262 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 7,983 | $139K |
| 80053 | Comprehensive metabolic panel | <1% | 15,424 | $109K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 29 | $103K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,024 | $101K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,945 | $91K |
| 96417 | <1% | 1,083 | $83K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,495 | $80K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 170 | $77K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 976 | $53K |
| 96416 | <1% | 335 | $49K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 297 | $43K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 4,739 | $39K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 111 | $38K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,471 | $38K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 176 | $35K |
| 96415 | <1% | 740 | $32K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,176 | $32K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 292 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,503 | $30K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 503 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 250 | $30K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 446 | $28K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,457 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 563 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,747 | $25K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,189 | $25K |
| 96411 | <1% | 420 | $24K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,741 | $21K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,150 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 231 | $20K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 278 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,334 | $19K |
| 86803 | <1% | 998 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 905 | $18K |
| 84702 | <1% | 1,926 | $18K | |
| 83735 | <1% | 3,387 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 309 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 432 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 442 | $16K |
| 84466 | <1% | 1,139 | $15K | |
| 96367 | <1% | 785 | $15K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 279 | $14K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 342 | $13K |
| 80050 | General health panel | <1% | 342 | $13K |
| 76830 | Ultrasound, transvaginal | <1% | 345 | $13K |
| 84484 | <1% | 2,357 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 211 | $12K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 887 | $12K |
| 82728 | <1% | 1,206 | $12K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 377 | $12K |
| 49452 | <1% | 525 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,324 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 543 | $11K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,423 | $11K |
| 86780 | <1% | 571 | $10K | |
| 80061 | Lipid panel | <1% | 775 | $10K |
| 87340 | <1% | 621 | $10K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 342 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 272 | $9K |
| 83615 | <1% | 1,545 | $9K | |
| 88185 | <1% | 46 | $9K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 72 | $9K |
| 86762 | <1% | 391 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,346 | $9K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 244 | $9K |
| 82784 | <1% | 465 | $9K | |
| 86850 | <1% | 1,354 | $8K | |
| 0002A | <1% | 172 | $8K | |
| 96402 | <1% | 281 | $8K | |
| 85027 | <1% | 1,172 | $8K | |
| 83540 | <1% | 1,135 | $8K | |
| 83690 | <1% | 2,848 | $7K | |
| 0001A | <1% | 160 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,102 | $7K |
| 82607 | <1% | 645 | $7K | |
| 81001 | <1% | 3,868 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 160 | $6K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 156 | $6K |
| 36591 | <1% | 218 | $6K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 79 | $6K |
| 86300 | <1% | 325 | $6K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 774 | $6K |
| 58571 | <1% | 12 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 231 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 836 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 617 | $5K |
| 84100 | <1% | 1,218 | $5K | |
| 59025 | Fetal non-stress test | <1% | 1,088 | $5K |
| J3490 | Unclassified drugs | <1% | 5,514 | $5K |
| 71250 | <1% | 74 | $5K | |
| 86334 | <1% | 217 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 150 | $5K |
| 96401 | <1% | 267 | $5K | |
| 84550 | <1% | 898 | $5K | |
| 83880 | <1% | 312 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $4K |
| 86900 | <1% | 1,397 | $4K | |
| 93971 | <1% | 100 | $4K | |
| 96376 | <1% | 605 | $4K | |
| 86901 | <1% | 1,389 | $4K | |
| 81025 | <1% | 2,484 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,221 | $4K |
| 80076 | <1% | 796 | $4K | |
| 76801 | <1% | 143 | $4K | |
| 82570 | <1% | 552 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 987 | $4K |
| 84439 | <1% | 507 | $4K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 76 | $3K |
| 93975 | <1% | 39 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 325 | $3K |
| 82378 | <1% | 253 | $3K | |
| 82746 | <1% | 345 | $3K | |
| 83605 | <1% | 773 | $3K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 329 | $3K |
| 89060 | <1% | 536 | $3K | |
| 36430 | <1% | 119 | $3K | |
| 87905 | <1% | 360 | $3K | |
| 87808 | <1% | 399 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,135 | $3K |
| 84165 | <1% | 222 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $3K |
| 85379 | <1% | 422 | $3K | |
| 88342 | <1% | 136 | $2K | |
| 70496 | <1% | 29 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 39 | $2K |
| 43235 | <1% | 12 | $2K | |
| 85610 | <1% | 1,049 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,195 | $2K |
| 87210 | <1% | 523 | $2K | |
| 82950 | <1% | 268 | $2K | |
| 83883 | <1% | 226 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,484 | $2K |
| 76642 | <1% | 43 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $2K |
| 73630 | <1% | 204 | $2K | |
| 85045 | <1% | 550 | $2K | |
| 70498 | <1% | 16 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,600 | $2K |
| 87081 | <1% | 382 | $2K | |
| 85730 | <1% | 466 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,250 | $2K |
| 83010 | <1% | 156 | $1K | |
| 81003 | <1% | 760 | $1K | |
| 87186 | <1% | 256 | $1K | |
| 84156 | <1% | 423 | $1K | |
| 73130 | <1% | 172 | $1K | |
| 86140 | <1% | 569 | $1K | |
| 88184 | <1% | 46 | $1K | |
| 84153 | <1% | 56 | $1K | |
| 83021 | <1% | 52 | $1K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $1K |
| 96523 | <1% | 89 | $1K | |
| 36593 | <1% | 49 | $1K | |
| 82043 | <1% | 125 | $1K | |
| 84145 | <1% | 152 | $1K | |
| 86592 | <1% | 217 | $981.00 | |
| 87481 | <1% | 25 | $951.69 | |
| 82550 | <1% | 253 | $942.70 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,960 | $921.43 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,699 | $915.18 |
| 87077 | <1% | 189 | $889.06 | |
| 96377 | <1% | 74 | $882.38 | |
| 85652 | <1% | 378 | $876.04 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $831.69 |
| 87040 | <1% | 95 | $828.71 | |
| 70486 | <1% | 12 | $825.15 | |
| 86038 | <1% | 50 | $820.26 | |
| 73610 | <1% | 73 | $745.03 | |
| 83986 | <1% | 510 | $742.80 | |
| 87070 | <1% | 109 | $720.41 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $711.10 |
| 81002 | <1% | 292 | $700.67 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $693.87 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,204 | $691.24 |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 16 | $690.28 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 44 | $688.96 |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 39 | $676.72 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,286 | $632.86 |
| 82962 | <1% | 946 | $597.52 | |
| 84163 | <1% | 29 | $586.37 | |
| 73562 | <1% | 59 | $546.50 | |
| 16020 | <1% | 20 | $519.20 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,264 | $500.17 |
| 87205 | <1% | 107 | $463.21 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,917 | $455.14 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 204 | $445.85 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 919 | $411.96 |
| 82565 | <1% | 89 | $389.48 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,707 | $389.01 |
| 73030 | <1% | 39 | $357.02 | |
| 84403 | <1% | 12 | $346.42 | |
| 99195 | <1% | 40 | $339.10 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,062 | $328.17 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,630 | $316.64 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,704 | $279.55 |
| C1769 | Guide wire | <1% | 220 | $271.79 |
| 88142 | <1% | 13 | $265.86 | |
| 87147 | <1% | 95 | $264.70 | |
| 84999 | <1% | 136 | $259.44 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,274 | $250.73 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,233 | $248.24 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 416 | $238.19 |
| 93017 | <1% | 15 | $225.29 | |
| 90715 | <1% | 81 | $224.21 | |
| 86255 | <1% | 12 | $215.69 | |
| 86923 | <1% | 32 | $214.20 | |
| 86706 | <1% | 15 | $213.92 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,400 | $204.93 |
| 76937 | <1% | 30 | $203.70 | |
| 88307 | <1% | 97 | $198.32 | |
| 82977 | <1% | 39 | $186.53 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 33 | $176.99 |
| 72100 | <1% | 14 | $170.11 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 302 | $155.99 |
| 80320 | <1% | 18 | $131.09 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 38 | $129.43 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 991 | $116.16 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 630 | $106.02 |
| 86431 | <1% | 12 | $102.65 | |
| 97161 | <1% | 143 | $95.42 | |
| 97165 | <1% | 90 | $92.60 | |
| 87486 | <1% | 18 | $87.50 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 18 | $83.49 |
| 85018 | <1% | 26 | $76.52 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 300 | $74.45 |
| J1815 | Injection, insulin, per 5 units | <1% | 437 | $74.33 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,091 | $69.66 |
| 88304 | <1% | 29 | $57.72 | |
| 87088 | <1% | 12 | $51.68 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,603 | $42.02 |
| 88311 | <1% | 12 | $39.99 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 42 | $35.98 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 358 | $33.39 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $30.45 |
| 74018 | <1% | 12 | $30.31 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 116 | $22.46 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 84 | $21.67 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 213 | $18.46 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 358 | $14.30 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,889 | $11.92 |
| S0030 | Injection, metronidazole, 500 mg | <1% | 113 | $6.26 |
| A9270 | Non-covered item or service | <1% | 26,405 | $0.31 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,544 | $0.01 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 19 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 368 | $0.00 |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 0% | 178 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 14 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 16 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 52 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 138 | $0.00 |
| 87581 | 0% | 18 | $0.00 | |
| J9312 | Injection, rituximab, 10 mg | 0% | 20 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 18 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 194 | $0.00 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 0% | 146 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 113 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 392 | $0.00 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 0% | 24 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 15 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 17 | $0.00 |
| 0100U | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIES, RICK (VICE PRESIDENT, FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Jefferson Regional Medical Center | Clairton, PA | $12.73M |
| West Penn Allegheny Health System INC. | Pittsburgh, PA | $10.81M |
| West Penn Allegheny Health System INC. | Monroeville, PA | $8.24M |
| Alle-Kiski Medical Center | Natrona Heights, PA | $6.09M |
| Canonsburg General Hospital | Canonsburg, PA | $2.97M |
| Grove City Medical Center | Grove City, PA | $2.17M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.